AbbVie Inc.
AbbVie Inc. (ABBV) — Form 8-K: Current report
AI-generated summary
AbbVie Inc. filed a current report detailing preliminary financial expectations for the third quarter of 2026. The company reported expected pre-tax acquired IPR&D and milestones expense of $216 million. AbbVie updated its full-year 2026 adjusted diluted earnings per share guidance range to $13.76 to $13.96 and its third-quarter 2026 range to $3.73 to $3.77.
Key facts
- Item 2.02 · Results of operations (earnings)
- Item 9.01 · Financial statements and exhibits
More ABBV filings
- 8-K
Filed Oct 30, 2026
- 3
Filed Oct 23, 2026
- 8-K
Filed Oct 15, 2026
- 4
Filed Oct 2, 2026
- 4
Filed Oct 2, 2026
- 8-K
Filed Sep 3, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.